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Introduction
Despite recent notable progress in medical sciences, cancer
remains a leading cause of human death worldwide,
accounting for about one-quarter of human deaths in
wealthy countries and about one-eighth worldwide (Ferlay
et al. 2010). In fact, the progress in cancer research has
been slower compared with that achieved related to other
pathologies, such as cardiovascular disorders. This is
mainly because of the enormous complexity of this disease,
which exhibits sophisticated cellular mechanisms that are
the targets of evolutionary processes driven by random
genetic and epigenetic mutations.
Indeed, cancer development and progression represent
evolutionary and ecological processes acted on by Dar-
winian selection, which drives cancer cells along evolution-
ary landscapes and culminates in resistance to immune
attack, malignant progression, metastasis, and sometimes
even contagion. It thus appears crucial to adopt this evolu-
tionary perspective for our understanding of cancer, its ori-
gin, the possible ways to control neoplastic progression,
and to prevent therapeutic failures (Merlo et al. 2006; Akti-
pis and Nesse 2013; Thomas et al. 2013).
Although these ideas originated in the mid-seventies,
many promising opportunities for the application of evolu-
tionary biology to carcinogenesis and oncology remain
unexplored and questions unanswered. For example, to
what extent do the evolutionary sciences offer relevant
tools for understanding and predicting cancer progression,
and are they more applicable to certain malignancies than
others? Can we alter the competition between cancerous
and noncancerous cells? What are the selective effects of
our therapies? Why and how do animal species differ in
their predisposition to cancer? These relevant questions
and many others were the focus of presentations and dis-
cussions at the Third Biannual International Evolution and
Cancer Conference that was held from 10 to 13 December
2015 in San Francisco (CA, USA). This conference brings
clinicians and evolutionary scientists from all over the
world (mostly the US, UK, and France) together every
2 years to present the latest advances in this growing field.
There were nearly 75 attendees at the 2015 conference.
The theme of this year was ‘Evolutionary Tradeoffs and
Clinical Consequences’. Trade-offs are pervasive in biologi-
cal systems, and the evolutionary dynamics underlying can-
cer are no exception. Conference presentations explored
the ways in which trade-offs have shaped the evolution of
cancer suppression systems and the role of trade-offs in the
progression of tumors from benign to malignant. A consid-
eration of evolutionary trade-offs can also help us to iden-
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tify challenges and opportunities in cancer therapies and
new horizons for cancer prevention.
Summary of presentations
The meeting started on 10 December with a keynote
address by Susan Rosenberg (Baylor College of Medicine,
Houston, TX, USA), who explained how bacteria and can-
cer cells regulate mutagenesis and their ability to evolve.
Dr. Rosenberg presented the molecular mechanism of
stress-induced mutation in Escherichia coli; she pointed out
the similarities with human cancer cells and suggested that
stress-control responses can regulate mutagenesis in time
and genomic space. Such an approach may lead to treat-
ments that focus on the evolutionary process rather than its
product.
The rest of the meeting was organized around several
plenary talks followed by sessions focused on the intro-
duced topic. On 11 December, Hanna Kokko (University
of Zurich, Switzerland) gave a plenary talk on the per-
spective of using cancer as a component of life-history
theory. She demonstrated the utility of understanding
cancer more broadly in wild animals (especially Peto’s
paradox, which is the unexpected absence of a relation-
ship between cancer incidence and animal body size,
and therefore the number of cells) to ultimately improve
prevention and/or treatment in humans. She also
showed that cancer is generally neglected as a factor in
life-history evolution.
Session ‘Organismal Evolution and Peto’s Paradox’
(chaired by Josh Schiffman, University of Utah Health
Care, Salt Lake City, UT, USA)
Speakers: Josh Schiffman, Leonard Nunney (University
of California, Riverside, CA, USA), and Robert Noble
(Institut des Sciences de l’Evolution, Montpellier,
France).
This session mostly focused on the possible explanations
of Peto’s paradox and the relevance of the field of compara-
tive oncology. These topics were addressed through exam-
ples at very different scales, from elephants and their
numerous copies of p53 (which protect them more effi-
ciently from cancer) to comparisons among human organs
according to their size. These talks highlighted the com-
plexity of this relationship because of the numerous trade-
offs involved and the specificity of each scale to respond to
the emergence of cancerous cells, from animal species to
different organ tissues.
The second plenary talk of the day was given by Sarah
Hill (Texas Christian University, Fort Worth, TX, USA),
who showed the link between life-history trade-offs and
vulnerability to cancer. She illustrated how life-history
trade-offs made in early life can increase cancer risk in
adulthood, especially how growing up in resource-poor
environments promotes eating in the absence of real neces-
sity (a pattern that promotes survivability in resource
scarce environments), which can in turn increase cancer
risk in environments that are food rich. Similarly, she
showed that individuals with less reactive NK cells (which
play a major role in the elimination of cancerous cells) are
generally associated with a range of behavioral outcomes
associated with faster life-history strategies (e.g., younger
age at reproduction, short life span), especially those
promoting cancer.
Session ‘Somatic Evolution and Cancer Stem Cells’
(chaired by Leonard Nunney, University of California,
Riverside, CA, USA)
Speakers: James de Gregori (University of Colorado,
Denver, Aurora, CO, USA CO, USA), Lucie Laplane
(Centre National de la Recherche Scientifique, Paris),
and Vincent Cannataro (University of Florida, Gaines-
ville, FL, USA).
This session covered the most recent progress into the
drivers of clonal evolution from the very different perspec-
tives of a philosophical point of view to in vivo experimen-
tation to in silico modeling. The role of aging, the causal
relationship between cancer stem cells and clonal evolution,
and the importance of considering clonal evolution in a
small stem cell population were discussed. These talks high-
lighted progress made in the understanding of clonal evolu-
tionary processes and also identified important gaps that
need to be filled. The day ended with a public lecture by
Barbara Natterson-Horowitz (University of California, Los
Angeles, CA, USA), who showed how veterinary science
can transform human medicine through evolutionary
biology.
The third day started with a plenary talk by Daniel Nettle
(Newcastle University, UK), who showed how early life
adversity affects cellular aging in the European starling
(Sturnus vulgaris). Using an experimental system, he
showed that early adversity, which could be nutritional
and/or social, can accelerate telomere attrition, which in
turn can be associated with altered adult behavior. Such
results demonstrate how early life events may accelerate cel-
lular aging and thus impact on the probability of cancer
emergence.
Parallel session ‘Tumor Heterogeneity’ (chaired by Carlo
Maley, Arizona State University, Tempe, AZ, USA)
Speakers: Oana Carja (University of Pennsylvania,
Philadelphia, PA, USA), Henry Heng (WayneState
University, Detroit, MI, USA), Diego Mallo (University
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of Vigo, Spain), Diego Chowell (Arizona State Univer-
sity), Pierre Martinez (Barts Cancer Institute, UK) and
Jeffrey Townsend (Yale School of Medicine, New Haven,
CT, USA).
This session explored the many different ways to charac-
terize the drivers of tumor heterogeneity, which is a core
problem in chemotherapy resistance. The session then
explored the different methodologies that can be used,
from agent-based modeling to the evolutionary analysis of
longitudinal single-cell clonal analysis. The importance of
treatment in the dynamics of tumor heterogeneity was also
discussed. It was shown that metastatic cancer does not
necessarily require sophisticated tumor heterogeneity and
that metastatic processes can begin quite early in the tumor
construction process.
Parallel session ‘Methods and Experimental Biology’
(chaired by Luca Ermini, Institute of Cancer Research,
London, UK)
Speakers: Robert Beardmore, Carlos Reding, Ivana Gudelj
(University of Exeter, UK); Luca Ermini and Mary Kuhner
(University of Washington, Seattle, WA, USA).
This session mostly focused on the combination of
experimental and theoretical studies that can determine the
drivers of genetic diversity observed in cancer. Talks sug-
gested than stable genetic polymorphisms can arise from
trade-offs in simple environments, but some trade-off
shapes can also underpin it. Other topics, such as an exten-
sion of the current r-K selection theory to explain the com-
plexity of cancerous cell resources or the hazards of
considering only driver and passenger mutations, were also
discussed.
The afternoon session began with a plenary talk by Joel
Brown (University of Illinois, Chicago, and Moffitt Cancer
Center, Tampa, FL, USA) on the mechanisms of coexis-
tence in tumor heterogeneity for which he drew analogies
with known ecological patterns in animal species commu-
nities. He emphasized the necessity for researchers working
on cancer evolution to consider the ecological part of this
evolution because tumors cannot be summarized only as a
collection of mutant genotypes and phenotypes, but rather
as some cell lineages that fill a finite number of distinct
niches.
Session ‘Evolutionary Approaches Relevant to Cancer
Treatment’ (chaired by Amy Boddy, ArizonaState
University, Tempe, AZ, USA)
Speakers: Mark Robertson-Tessi, Amy Boddy, Chandler
Gatenbee (Moffitt Cancer Research Center, Tampa, FL,
USA); William Chang (Albert Einstein College of Medicine,
New York, NY, USA).
The aim of this session was to show how evolutionary
approaches could bring new solutions to the struggle
against cancer. One solution proposed by Robertson-Tessi
solution was the possibility of combining different
therapies targeting different aspects of clonal evolution
(especially phenotypic plasticity) to avoid resistance to
chemotherapy; this solution used a mathematical model
calibrated with an experimental model. The importance of
the spatial dimension was covered extensively, including
the emergence of resistance and cellular strategies to escape
attack from the immune system.
The day ended with a keynote address by Marco Ger-
linger (The Institute of Cancer Research, London, UK)
on the tools available to reconstruct and predict the evo-
lution of cancerous cells. Using large-scale and ultra-sen-
sitive genomic technologies, evolutionary trajectories of
tumors can be described and quantified. Moreover, phe-
notype-directed genetic analyses start to reveal the poten-
tial functional effects of newly acquired genotypes. This
talk ended with some suggestions for future research that
could help to predict the evolutionary dynamics within a
tumor.
The last day started with a plenary talk given by Aurora
Nedelcu (University of New Brunswick, Fredericton, NB,
Canada) on the possibility to exploit trade-offs to under-
stand and expose cancer’s evolutionary vulnerabilities.
Using experimental evolutionary systems, she showed how
we can identify the new trade-offs that emerge in cancerous
cells and what potential weak points could be exploited for
future treatments.
Session ‘Cancer on the Evolution of Life’ (chaired by
Athena Aktipis, Arizona State University, Tempe, AZ,
USA)
Speakers: Frederic Thomas (Center for Ecological and Evo-
lutionary Research on Cancer, Montpellier, France);
Athena Aktipis, Jekaterina Erenpreisa (Latvian Biomedical
Research and Study Centre, Latvia); Carlo Maley (Biode-
sign Institute, School of life Sciences, Arizona State Univer-
sity, Tempe AZ, USA).
This last session focused on the impact of cancer on the
evolution of organisms. Using experimental and theoretical
systems, different impacts of cancer on an organism’s life-
history traits—from fecundity to life cycles through cellular
competition and cancer susceptibility—were discussed.
The last talk by Carlo Maley covered the main problems in
cancer biology (namely risk stratification, prevention, early
detection, therapeutic responses, and acquired therapeutic
resistance) and discussed how evolutionary ecology has
recently been applied to them.
A poster session was also organized that were presented
by 15 teams of researchers from several countries around
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the world. A broad range of topics were addressed, includ-
ing the role of immunity, the influence of vitamin C on
cancer, and the different ways to connect clonal evolution
to tumor heterogeneity. The award for the best poster was
presented to Camille Jacqueline (Center for Ecological and
Evolutionary Research on Cancer, Montpellier, France) for
her work on the indirect role of infectious diseases on the
proliferation of cancer cells through immune system trade-
offs.
Creation of the international society for evolution,
ecology and cancer
This conference was the first to be organized under the
responsibility of the International Society for Evolution,
Ecology and Cancer (ISEEC), which was created on this
occasion. The mission of this scientific society is to
advance cancer research and clinical management by
employing evolutionary, comparative, and ecological
approaches and principles to cancer biology, prevention,
and treatment. By bringing together cancer biologists,
evolutionary biologists, ecologists, quantitative modelers,
bioinformaticians, and clinicians, the society seeks to
enable collaboration at the interface of these fields and to
promote the exchange of research findings, novel
methodologies, and theoretical frameworks across disci-
plines. ISEEC supports education and outreach efforts to
train the next generation of scientists in the evolution
and ecology of cancer and also engages the public in fun-
damental questions about the nature and evolutionary
origins of cancer.
This three-day conference was the third one organized
on the topic of evolution and cancer; the two previous
conferences also took place in San Francisco (in 2011 and
2013). Even though the scientific community in this new
discipline is not yet growing very rapidly, the variety of the
topics addressed highlights the dynamism of this emerging
scientific field. Moreover, vastly different perspectives have
been examined—from the impact of cancer on the evolu-
tion of life to the impact of evolution on cancer. New excit-
ing insights for both the evolutionary and medical
communities can be expected in the near future.
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